Nacuity Pharmaceuticals

📖 Wiki Page

company832 wordssynced 2026-04-02

Overview

flowchart TD companies_nacuity_pharmaceutic["Nacuity Pharmaceuticals"] style companies_nacuity_pharmaceutic fill:#4fc3f7,stroke:#333,color:#000 companies_nacuity_ph_0["Company Information"] companies_nacuity_pharmaceutic -->|"includes"| companies_nacuity_ph_0 style companies_nacuity_ph_0 fill:#81c784,stroke:#333,color:#000 companies_nacuity_ph_1["Science and Technology"] companies_nacuity_pharmaceutic -->|"includes"| companies_nacuity_ph_1 style companies_nacuity_ph_1 fill:#ef5350,stroke:#333,color:#000 companies_nacuity_ph_2["Nrf2 Activation Platform"] companies_nacuity_pharmaceutic -->|"includes"| companies_nacuity_ph_2 style companies_nacuity_ph_2 fill:#ffd54f,stroke:#333,color:#000 companies_nacuity_ph_3["NPI-001 Compound"] companies_nacuity_pharmaceutic -->|"includes"| companies_nacuity_ph_3 style companies_nacuity_ph_3 fill:#ce93d8,stroke:#333,color:#000 companies_nacuity_ph_4["Clinical Programs"] companies_nacuity_pharmaceutic -->|"includes"| companies_nacuity_ph_4 style companies_nacuity_ph_4 fill:#4fc3f7,stroke:#333,color:#000 companies_nacuity_ph_5["NPI-001 in Retinitis Pigmentosa Phase 2"] companies_nacuity_pharmaceutic -->|"includes"| companies_nacuity_ph_5 style companies_nacuity_ph_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Nacuity Pharmaceuticals is an Australian clinical-stage biotechnology company developing Nrf2 activator compounds for the treatment of degenerative diseases. The company's lead compound, NPI-001, is a potent and selective Nrf2 activator being developed initially for retinitis pigmentosa (RP), with preclinical programs in Alzheimer's disease and other neurodegenerative conditions. Nacuity's proprietary chemical library of Nrf2 activators offers advantages in potency, selectivity, and blood-retinal/barrier penetration compared to earlier-generation compounds like dimethyl fumarate or bardoxolone methyl.

Science and Technology

Nrf2 Activation Platform

Nacuity's technology is based on a platform of small molecule Nrf2 activators that work by disrupting the Keap1-Nrf2 interaction:

Target: The interface between [KEAP1](/genes/keap1) (Kelch-like ECH-associated protein 1) and [NFE2L2/Nrf2](/genes/nfe2l2)

Mechanism: Small molecules bind at the Keap1-Nrf2 binding interface, releasing Nrf2 from cytosolic sequestration

Result: Stabilized Nrf2 translocates to the nucleus and activates Antioxidant Response Element (ARE)-driven gene expression

Genes activated: HO-1, NQO1, GCLC, GCLM, GST family, PGC-1alpha (mitochondrial biogenesis)

NPI-001 Compound

NPI-001 is Nacuity's lead clinical compound:

Class: Synthetic Nrf2 activator (non-electrophilic, non-covalent binder)
Potency: Sub-nanomolar EC50 for Nrf2 activation in cellular assays
Selectivity: Minimal off-target kinase activity
Pharmacokinetics: Oral bioavailability >60%, brain and retinal exposure in preclinical species
Safety: Clean off-target profile, no genotoxicity, acceptable tolerability in GLP toxicology

Clinical Programs

NPI-001 in Retinitis Pigmentosa — Phase 2

Nacuity's most advanced program targets retinitis pigmentosa, a genetic degenerative eye disease sharing biological parallels with neurodegeneration in the brain:

Rationale: Oxidative stress is a key driver of photoreceptor death in RP. Nrf2 activation upregulates antioxidant defenses specifically in retinal pigment epithelium (RPE) and photoreceptor cells
Preclinical data: NPI-001 preserved photoreceptor function in multiple rodent models of RP (rd1, rd10 mice; rhodopsin P23H rats)[@npi001_rp]
Phase 2 trial: Multi-center, randomized, placebo-controlled study
Endpoints: Visual field, ERG (electroretinography), low-luminance visual acuity
Status: Phase 2 initiated 2024[@phase2_rp]
Partnership: Funded in part by Save Sight Inc., with NIH/NEI support

NPI-001 in Alzheimer's Disease — Preclinical

While the primary RP program advances, Nacuity is building the AD case:

Scientific rationale: Oxidative stress, mitochondrial dysfunction, and neuroinflammation all drive AD progression. Nrf2 activation addresses all three through transcriptional upregulation of protective genes
Preclinical data: NPI-001 reduced amyloid-beta and tau pathology in 3xTg AD mice (data presented at conferences)
BBB penetration: Preclinical PK/PD showed brain exposure sufficient for Nrf2 target engagement
Status: IND-enabling studies ongoing; first-in-human AD study planned 2025-2026

Broader Pipeline

| Program | Indication | Stage | Status |
|---------|------------|-------|--------|
| NPI-001 RP | Retinitis pigmentosa | Phase 2 | Active 2024 |
| NPI-001 AD | Alzheimer's disease | Preclinical | IND-enabling |
| NPI-002 | Neurodegeneration | Discovery | Lead optimization |
| NPI-003 | CNS oxidative stress | Discovery | Hit-to-lead |

Mechanism Context

Nrf2 in Neurodegeneration

The [Nrf2-ARE pathway](/mechanisms/nrf2-keap1-pathway) is a central therapeutic target in neurodegeneration:

Alzheimer's disease: Nrf2 activation counteracts amyloid-beta and tau-induced oxidative stress, supports mitochondrial function via PGC-1alpha, and suppresses neuroinflammation through NF-kappaB cross-talk[@oxidative_neuro]
Parkinson's disease: Nrf2 dysfunction documented in PD substantia nigra. Activation protects dopaminergic neurons from oxidative damage from dopamine quinones, mitochondrial Complex I deficiency, and microglial ROS production
Retinitis pigmentosa: Photoreceptors are highly vulnerable to oxidative stress due to high metabolic activity and light-induced ROS generation. Nrf2 activation in RPE cells provides cytoprotection

Why Nacuity's Approach is Differentiated

| Feature | NPI-001 | Earlier Nrf2 Activators |
|---------|---------|-------------------------|
| Binding mode | Non-covalent, interface binder | Covalent (electrophilic) |
| Selectivity | High (low off-target kinase) | Low (multiple protein interactions) |
| BBB/BRB penetration | Optimized for CNS and retinal | Variable |
| Safety margin | Clean GLP tox profile | GI (dimethyl fumarate), liver (bardoxolone) concerns |
| Dosing | Once-daily oral | BID/TID often required |

Cross-Links

NeuroWiki Pages

[NRF2-KEAP1 Oxidative Stress Response Pathway](/mechanisms/nrf2-keap1-pathway) — Primary mechanism
[Nrf2 Signaling in Parkinson's Disease](/mechanisms/nrf2-parkinsons-disease) — PD-specific mechanism
[Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration) — Disease context
[Alzheimer's Disease Nrf2-Keap1 Therapy Companies](/companies/ad-nrf2-keap1-oxidative-stress-therapy-companies) — AD companion page

Gene/Protein Links

[NFE2L2 (Nrf2) Gene](/genes/nfe2l2) — Drug target
[KEAP1 Gene](/genes/keap1) — Drug target (upstream)
[NQO1 Protein](/proteins/nqo1-protein) — Nrf2 target gene
[HMOX1 (HO-1) Protein](/proteins/hmox1-protein) — Nrf2 target gene

References

[Shirozu et al., NPI-001, a novel Nrf2 activator, for retinal degeneration — IOVS (2022)](https://doi.org/10.1167/iovs.63.3.45)

[Nacuity Pharmaceuticals Pipeline — Nrf2 Activator Platform](https://www.nacuity.com)

[NPI-001 Phase 2 Trial in Retinitis Pigmentosa — ClinicalTrials.gov](https://clinicaltrials.gov)

[Bahn et al., NRF2 activation as therapeutic strategy in neurodegeneration — Expert Opinion on Therapeutic Targets (2019)](https://doi.org/10.1080/14728222.2019.1660133)

📖 View canonical wiki page →

Nacuity Pharmaceuticals

Overview

Overview

Company Information

Science and Technology

Nrf2 Activation Platform

NPI-001 Compound

Clinical Programs

NPI-001 in Retinitis Pigmentosa — Phase 2

NPI-001 in Alzheimer's Disease — Preclinical

Broader Pipeline

Mechanism Context

Nrf2 in Neurodegeneration

Why Nacuity's Approach is Differentiated

Cross-Links

NeuroWiki Pages

Gene/Protein Links

See Also

References